Salcaprozate sodium

Salcaprozate sodium, commonly called SNAC, is the sodium salt of 8-(2-hydroxybenzamido)octanoic acid used in oral drug-delivery development. In oral semaglutide formulations, it raises the local pH around the dissolving tablet, helping protect the peptide from gastric enzymatic degradation. It also promotes transcellular uptake across the gastric epithelium near the tablet surface.

The selected material is the sodium-carboxylate form used as a functional formulation component. Its role depends on close co-release with the peptide, making the local tablet microenvironment central to performance. Semaglutide provides an established application; use with other peptide molecules remains a formulation-development question requiring molecule-specific evidence. This distinguishes the excipient’s documented local gastric action from a general claim that it improves absorption of every oral active ingredient.

Typical Applications

• Oral semaglutide formulations: Used as a coformulated absorption enhancer in tablet development, supporting local peptide protection and gastric uptake during tablet dissolution.
• Experimental oral-peptide delivery: Used in exploratory peptide formulations to investigate whether co-release with SNAC produces adequate stability and absorption for the particular candidate molecule.
• Gastric delivery-mechanism studies: Used in experimental models of tablet-surface pH, peptide degradation and epithelial transport to study how the local formulation environment affects uptake.

Specifications

Specifications describe the standard grade. Tolerance, test method and documentation package are confirmed per order.